VSTMVerastem, Inc.Running, no new patients
A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients
Low Grade Serous Ovarian Cancer · Ovarian Cancer
12Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +11.5
A key executive is leaving
Since Oct 14, 2026 · was worth 15, fading over time
Worry score12
Score over time
- Stage
- Phase 2
- Patients
- 16 (final count)
- Started
- Oct 30, 2024
- Main results expected
- Dec 2025
- Fully finished
- Oct 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Confirmed overall response rate (ORR; partial response [PR] + complete response [CR]
Measured over: From start of treatment to confirmation of response; 24 weeks
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- key_exec_departure: base 15, now 11.5, since 2026-10-14, fades (half-life) · source filing
Raw record changes
- none yet
Trial ID NCT06682572 · record last updated 2025-12-17 · checked 2026-11-09 15:42 UTC